Europe shares dip early; Actelion up on drug results
* FTSEurofirst 300 down 0.2 pct, Euro STOXX 50 down 0.5 pct
* Actelion jumps 14 percent on positive results for Selexipag
* BNP up after French finmin's comments on U.S. talks
By Blaise Robinson
PARIS, June 16 (Reuters) - European stocks slipped in early trade on Monday, adding to last week's retreat as mounting violence in Iraq prompted investors to lock in more of their profits on recent equity market gains.
Shares in Denmark's Vestas dropped 4.2 percent after Barclays cut its recommendation on the world's biggest wind turbine maker to 'underweight' from 'equal weight', saying the stock is overvalued.
Swiss biotech group Actelion Ltd bucked the trend, surging 14 percent after it said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving it a potential second big seller.
But as of 0806 GMT, the FTSEurofirst 300 index of top European shares was down 0.2 percent at 1,386.45 points, retreating further from a 6-1/2 year high hit last week.
The euro zone's blue-chip Euro STOXX 50 index was down 0.5 percent, at 3,267.22 points. Continuación...